이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

정신과의 흡연 감소에 대한 중재 연구 (TABAPSY)

2026년 10월 7일 업데이트: GCS-CCOMS

외래 정신과에서 치료받은 정신 건강 사용자의 흡연을 줄이기위한 중재 평가

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.

The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

연구 개요

상태

모병

정황

상세 설명

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.

While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.

Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:

  1. A general information meeting, to encourage motivation to start smoking cessation;
  2. An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
  3. Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
  4. Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.

The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.

A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).

It will be supplemented by a qualitative study to study the implementation of the intervention.

All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.

6,250 participants will be included over 12 months, in 22 participating sectors.

연구 유형

중재적

등록 (추정된)

6500

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Saint-Claude, 과들루프, 97122
        • 모병
        • Public mental health establishment of Guadeloupe (96G06)
        • 연락하다:
        • 수석 연구원:
          • Isabelle DELAROZIERE, MD
      • Saint-Claude, 과들루프, 97122
        • 모병
        • Public mental health establishment of Guadeloupe (96G01)
        • 연락하다:
        • 수석 연구원:
          • Magloire MPEMBI, MD
      • Saint-Paul, 재결합, 97460
        • 완전한
        • Public mental health establishment of Reunion Island (Pôle Nord)
      • Armentières, 프랑스, 59280
        • 완전한
        • Public mental health establishment of Lille Metropole (59G16-G17)
      • Armentières, 프랑스, 59280
        • 완전한
        • Public mental health establishment of Lille Metropole (59G21)
      • Bailleul, 프랑스, 59270
        • 완전한
        • Flanders public mental health establishment (59G05/06)
      • Laxou, 프랑스, 54520
        • 완전한
        • Psychotherapeutic center of Nancy (54G02-06)
      • Lille, 프랑스, 59000
        • 빼는
        • University Hospital Center of Lille (59G08)
      • Nanterre, 프랑스, 92014
        • 완전한
        • Hospital Care Center of Nanterre (92G10)
      • Paris, 프랑스, 75014
        • 완전한
        • University Hospital Group Paris Neurosciences & Psychiatry (75G04)
      • Rouffach, 프랑스, 68250
        • 완전한
        • Hospital Center of Rouffach (68G02/03)
      • Rouffach, 프랑스, 68250
        • 완전한
        • Hospital Center of Rouffach (68G08/09)
      • Rouffach, 프랑스, 68250
        • 완전한
        • Hospital Center of Rouffach (Pôle LTD - 68G04/05)
      • Saint-Maurice, 프랑스, 94410
        • 완전한
        • Hospitals of Paris Est Val de Marne (94G01)
      • Saint-Maurice, 프랑스, 94410
        • 완전한
        • Hospitals of Paris Est Val de Marne (94G16)
      • Saint-Maurice, 프랑스, 94410
        • 완전한
        • Hospitals of Paris Est Val de Marne (Paris 11)
      • Saint-Maurice, 프랑스, 94410
        • 완전한
        • Hospitals of Paris Est Val de Marne (Paris 12)
      • Saint-Maurice, 프랑스, 94410
        • 완전한
        • Hospitals of Paris Est Val de Marne (Paris Centre)
      • Saint-Venant, 프랑스, 62350
        • 완전한
        • Public mental health establishment of Val de Lys Artois (62G09)
      • Saint-Venant, 프랑스, 62350
        • 완전한
        • Public mental health establishment of Val de Lys Artois (62G12)
      • Saint-Venant, 프랑스, 62350
        • 완전한
        • Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
      • Étampes, 프랑스, 91150
        • 모병
        • Barthelemy Durand public health establishment (91G05)
        • 연락하다:
        • 수석 연구원:
          • Amina AMRANDI, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Regular smokers (at least one cigarette per day)
  • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
  • Adults (18 years or older)
  • Covered by the statuary health insurance
  • Who gave their informed consent to participate to the study

Exclusion Criteria:

  • Users under guardianship or legal protection,
  • Psychological state incompatible with completing the questionnaire,
  • Persons with no command or understanding of the French language

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Intervention arm

Sectors randomized to the intervention group will implement the 'Tabapsy' intervention.

The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur

다른: Usual care

Sectors randomized to the control group will continue implementing their usual smoking cessation promotion.

Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Short-term smoking cessation
기간: 3 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

3 months

2차 결과 측정

결과 측정
측정값 설명
기간
Motivation to stop smoking
기간: 3 and 6 months

The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation.

3 and 6 months
Voluntary quit attempts lasting at least 24 hours in the last 3 months
기간: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use

3 and 6 months
Voluntary quit attempts lasting at least 7 days in the last 3 months
기간: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user.

3 and 6 months
Tobacco consumption
기간: 3 and 6 months

Number of cigarettes smoked per day

3 and 6 months
Nicotine dependence
기간: 3 and 6 months

Nicotine dependence will be measured by the 6-question Fagerström test.

3 and 6 months
Short-term smoking cessation
기간: 6 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

6 months
Medium-term smoking cessation
기간: At 3 and 6 months

Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study.

At 3 and 6 months
Use of smoking cessation aids
기간: 3 and 6 months

Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately

3 and 6 months
Level of mental well-being
기간: 3 and 6 months

Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being

3 and 6 months
Level of physical well-being
기간: 3 and 6 months

Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being

3 and 6 months
Knowledge and representations surrounding tobacco use
기간: 3 and 6 months

Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop

3 and 6 months
Cost-effectiveness (short-term)
기간: A 6 months

Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days.

A 6 months
Cost-effectiveness (long-term)
기간: 6 months

Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased.

6 months
Budgetary impact (costs)
기간: 5 years after hypothetical generalization

Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization.

5 years after hypothetical generalization
Budgetary impact (health benefits)
기간: 5 years after hypothetical generalization

The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization.

5 years after hypothetical generalization
Implementation
기간: 6 months

The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group).

6 months
Satisfaction level
기간: 3 and 6 months

Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction.

3 and 6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jean-Luc ROELANDT, MD, GCS-CCOMS & INSERM ECEVE 1123
  • 연구 책임자: Karine CHEVREUL, MD and Pr of public health, Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 15일

기본 완료 (실제)

2026년 7월 15일

연구 완료 (추정된)

2026년 11월 14일

연구 등록 날짜

최초 제출

2025년 2월 18일

QC 기준을 충족하는 최초 제출

2025년 4월 7일

처음 게시됨 (실제)

2025년 4월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 7일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 2024-A01474-43
  • A19017HS (기타 식별자: Institute for Public Health Research (IRESP))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다